Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics of patients with seasonal allergic rhinitis and concomitant asthma.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2004
Same author

Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2001
Same author

Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma.

The Journal of allergy and clinical immunology·2000
Same author

The effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma: a pooled analysis of three trials.

Chest·1998
Same author

Emergency treatment of acute asthma with albuterol metered-dose inhaler plus holding chamber: how often should treatments be administered?

Chest·1997
Same author

A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma.

Chest·1996
Same journal

Usability and Acceptance of Autoinjector and Prefilled Syringe Devices by Patients with Generalized Myasthenia Gravis in a Human Factors Study.

Advances in therapy·2026
Same journal

Treatment Patterns and Decision Drivers in Chinese Patients with Locally Advanced Cervical Cancer: Results from a National Physician Survey.

Advances in therapy·2026
Same journal

Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer.

Advances in therapy·2026
Same journal

Sacral Neuromodulation for Refractory Overactive Bladder: Closing the Gaps in Anatomy, Mechanisms, and Parameter Selection.

Advances in therapy·2026
Same journal

Exploring the Impact of Delivering Allergy Medication as Self-Care on Healthcare Greenhouse Gas Emissions in the United Kingdom.

Advances in therapy·2026
Same journal

Management of Persistent Storage Symptoms and Overactive Bladder in Men Diagnosed with Benign Prostatic Hyperplasia: A Narrative Review.

Advances in therapy·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

An easy-to-use dry-powder inhaler.

J P Karpel1

  • 1Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.

Advances in Therapy
|April 25, 2001
PubMed
Summary
This summary is machine-generated.

This new mometasone furoate dry-powder inhaler simplifies asthma treatment with a three-step process. It ensures accurate medication delivery, supporting patient adherence for persistent asthma in adults and children.

More Related Videos

Intratracheal Administration of Dry Powder Formulation in Mice
07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

Disposable Dosators Intended for Dry Powder Delivery to Mice
04:59

Disposable Dosators Intended for Dry Powder Delivery to Mice

Published on: August 18, 2023

Related Experiment Videos

Last Updated: Jun 21, 2026

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

Intratracheal Administration of Dry Powder Formulation in Mice
07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

Disposable Dosators Intended for Dry Powder Delivery to Mice
04:59

Disposable Dosators Intended for Dry Powder Delivery to Mice

Published on: August 18, 2023

Area of Science:

  • Respiratory Medicine
  • Pharmacology
  • Medical Device Technology

Background:

  • Persistent asthma requires consistent medication adherence for effective management.
  • Topical corticosteroids are a cornerstone treatment for persistent asthma.
  • Novel inhaler devices aim to improve drug delivery and patient compliance.

Purpose of the Study:

  • To evaluate a novel mometasone furoate dry-powder inhaler (MF-DPI) designed for enhanced patient compliance.
  • To assess the accuracy, uniformity, and precision of drug delivery from the MF-DPI across varying inspiratory flow rates.
  • To determine the clinical efficacy of the MF-DPI in treating persistent asthma in adult and pediatric populations.

Main Methods:

  • Development of a breath-actuated dry-powder inhaler utilizing a stabilized agglomerate formulation.
  • Laboratory testing to evaluate dose measurement and delivery accuracy, uniformity, and precision.
  • Clinical trials to assess the efficacy and usability of the MF-DPI in patients with persistent asthma.

Main Results:

  • The MF-DPI demonstrated accurate, uniform, and precise drug delivery over a range of inspiratory flow rates.
  • Laboratory and clinical data confirmed the device's effectiveness.
  • The inhaler's simple three-step operation was designed to support patient compliance.

Conclusions:

  • The novel mometasone furoate dry-powder inhaler is a clinically effective device for treating mild, moderate, and severe persistent asthma.
  • The inhaler's design facilitates accurate corticosteroid delivery and supports improved patient adherence.
  • This device offers a promising therapeutic option for adult and pediatric asthma patients aged 12 and older.